Taris Biomedical LLC
5
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
1 terminated/withdrawn out of 5 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Role: lead
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Role: lead
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
Role: lead
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
Role: lead
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
Role: lead
All 5 trials loaded